Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Urology|May 28, 2021
Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective StudyPeter Gilling, Patrick Meffan, Bilal Kaaki, et al.
European Urology|April 24, 2013
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trialChristopher Chapple, Karl-Dietrich Sievert, Scott MacDiarmid, et al.
Current Medical Research and Opinion|February 21, 2018
Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settingsMichael Kennelly, Lonny Green, Nancy Alvandi, et al.
International Urogynecology Journal|May 27, 2014
Validation of a bladder symptom screening tool in women with incontinence due to overactive bladderLinda Cardozo, David Staskin, Brooke Currie, et al.
BMC Neurology|July 11, 2013
Development of a short form and scoring algorithm from the validated actionable bladder symptom screening toolDavid Bates, Jack Burks, Denise Globe, et al.
International Journal of MS Care|January 24, 2014
Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patientsJack Burks, Michael Chancellor, David Bates, et al.
The Journal of Urology|April 24, 2019
Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary IncontinenceScott MacDiarmid, David R Staskin, Vincent Lucente, et al.
International Journal of Clinical Practice|April 19, 2017
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)Marcus J Drake, Scott MacDiarmid, Christopher R Chapple, et al.
European Urology|March 12, 2016
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)Marcus J Drake, Christopher Chapple, Ahmet A Esen, et al.
The Journal of Urology|April 12, 2016
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected]Scott MacDiarmid, Salman Al-Shukri, Jack Barkin, et al.
Pageof 4